Amplia is pleased to announce that new preclinical data and updated data from the ongoing ACCENT trial in pancreatic cancer, was presented overnight at the prestigious Keystone meeting ‘Tumor Microenvironment: Metastasis and the Host’ in Banff, Canada.
The poster describes preclinical data for narmafotinib in models of pancreatic cancer and presents further analysis of data from the Phase 1b portion of the ACCENT trial.
Data highlights from the presentation include:
- Evidence from the Phase 1b stage of the ACCENT trial that there is a dose-dependent reduction in tumour size, as the oral dose of drug increases from 100 mg to 200 mg to 400 mg
- Data showing that patients on the 400 mg dose of narmafotinib had an average treatment duration of 8.3 months, significantly better than historical data for patients receiving chemotherapy alone
- Demonstration that narmafotinib has anti-fibrotic effects in a mouse model of pancreatic cancer and that narmafotinib has single-agent activity in this model
- Demonstration that narmafotinib enhances the activity of chemotherapy and appears to inhibit resistance to the chemotherapy that develops over time in the mouse model
In addition, the poster shows preliminary data demonstrating the beneficial effects of narmafotinib when combined with the approved drug adagrasib in mouse models of cancer.
Amplia CEO, Dr Chris Burns, commented:
“We are delighted to present further data about our drug narmafotinib and its activity in the ACCENT clinical trial. Demonstration of the drug’s activity in cancer patients, as well as in defined animal models of cancer, helps to build a robust dataset that underpins the commercial potential of the drug.”
Click to read the ASX release.
